TOKYO -- South Korean drugmaker Celltrion has recorded positive preclinical results for its coronavirus treatment, the company announced on Monday.
The pharmaceutical group said the experimental drug, which assessed efficacy in animals, demonstrated a 100-fold reduction in the viral load of COVID-19.
